Abstract:6000 Background: The benefit of concurrent chemotherapy to treat intermediate-risk (stage II and T3N0M0) nasopharyngeal carcinoma (NPC) remains controversial. We aimed to assess whether concurrent chemotherapy can be omitted safely for intermediate-risk NPC patients treated with intensity-modulated radiotherapy. Methods: This multi-centre, noninferiority, open-label, randomised controlled, phase III trial was done at 4 hospitals in China. Patients aged 18–65 years, with histologically confirmed, stage T1-2N1/T2-3N0M0, a Karnofsky score of at least 70 were randomly assigned (1:1) to receive either concurrent chemoradiotherapy (CCRT) (cisplatin 100 mg/m² on days 1, 22, and 43) or radiotherapy alone (RT). Key exclusion criteria included: maximal axial diameter of neck lymph node ≥30mm, positive neck lymph node at level IV or lower, pretherapy plasma EBV DNA level ≥4000 copy/ml. Randomisation was performed with a random number code stratified by treatment centre and stage. The primary endpoint was failure-free survival（FFS).The calculated sample size was 169 per group, with an 80% power (one-sided α 0.05). Results: Between November 11, 2015 and August 4, 2020, 341 NPC patients were randomly assigned to receive either RT (n=172) or CCRT（n=169). After a median follow-up of 41 months, intention-to-treat analysis showed that 3-year FFS was 90.7% (95% CI 86.2–95.2) in the RT group, and 92.1% (95%CI 88.8–96.4) in the CCRT group, with a difference of -1.4% (upper limit of the one-sided 95% CI 4.5; p non-inferiority =0.00017). Similarly excellent FFS was found in the per-protocol analysis: 3year FFS for RT versus CCRT was 90.3% (95% CI 85.6–95.0) and 92.1% (95% CI 87.8–96.4), respectively, with a difference of -1.8% (upper limit of the one-sided 95% CI 4.3; p non-inferiority =0.00014). No differences were observed between groups in terms of overall survival, locoregional relapse and distant metastasis. Patients in the CCRT group developed significantly more grade 3-4 hematologic and nonhematologic adverse events such as vomiting (CCRT group 14.8% vs. RT group 1.2%), anorexia (29.9% vs. 4.8%), mucositis (18.9 % vs. 9.7%) and weight loss(4.7% vs. 0.6%). No patients died from treatment-related causes. Conclusions: Radiotherapy alone provides comparable disease control or survival and less toxicity compared to CCRT in the intermediate risk NPC. Clinical trial information: NCT02633202. RT group(%) CCRT group (%) P value Intention-to-treat population n = 172 n = 169 3-yr overall survival 98.7 99.4 0.178 3-yr distant metastasis-free survival 95.6 98.1 0.136 3-yr locoregional recurrence-free survival 94.4 93.9 0.975 Per-protocol population n = 165 n = 169 3-yr overall survival 98.7 99.4 0.159 3-yr distant metastasis-free survival 95.4 98.1 0.118 3-yr locoregional recurrence-free survival 94.2 93.9 0.890

Chemo-radiotherapy Versus Radiotherapy Alone for Nasopharyngeal Carcinoma: A Meta-Analysis of 78 Randomized Controlled Trials (rcts) from English and Non-English Databases

A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma

Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: A Systemic Review and Meta-analysis of 2138 Patients

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up

Radiotherapy Alone Versus Concurrent Chemoradiotherapy in Intermediate Risk Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Noninferiority, Randomised Phase III Trial.

Role of Chemoradiotherapy in Intermediate Prognosis Nasopharyngeal Carcinoma

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

Use of Taxane-Containing Induction Chemotherapy in Combination with Concurrent Chemoradiotherapy in Chinese Patients with Locally Advanced Nasopharyngeal Carcinoma: a Meta-Analysis

Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II–IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis

Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study

Combined CT-guided Radiofrequency Ablation with Systemic Chemotherapy Improves the Survival for Nasopharyngeal Carcinoma with Oligometastasis in Liver: Propensity Score Matching Analysis

Preliminary Results of a Phase III Randomized Study Comparing Chemotherapy Neoadjuvantly or Concurrently with Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

A Network Meta-Analysis for Efficacies and Toxicities of Different Therapeutic Regimens in the Treatment of Advanced Nasopharyngeal Carcinoma.

T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma

Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study

Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma

Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors